NASDAQ : XBIO
Xenetic Biosciences, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 2.12 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 4.97M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Xenetic Biosciences, Inc. (XBIO) reported revenue of 3.26M USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Revenue | 3.26M | 2.98M | 2.50M | 2.54M | 1.71M | 1.16M |
| Gross Profit | 3.26M | 2.98M | 2.50M | 2.54M | 1.71M | 1.16M |
| Selling, General & Admin | 3.16M | 2.75M | 3.42M | 3.56M | 3.65M | 3.74M |
| Research & Development | 2.74M | 3.07M | 3.29M | 3.49M | 4.77M | 3.16M |
| Operating Expenses | 5.90M | 5.81M | 6.70M | 7.06M | 8.42M | 6.91M |
| Operating Income | -2.64M | -2.83M | -4.20M | -4.52M | -6.72M | -5.75M |
| Interest & Investment Income | 162.40K | 148.00K | 249.86K | 355.76K | 167.15K | 100.47K |
| Other Non Operating Income (Expenses) | 4.08K | 5.72K | -5.71K | 25.38K | -1.60K | 1.12K |
| EBT Excluding Unusual Items | -2.48M | -2.68M | -3.96M | -4.13M | -6.55M | -5.65M |
| Pretax Income | -2.48M | -2.68M | -3.96M | -4.13M | -6.55M | -5.65M |
| Net Income | -2.48M | -2.68M | -3.96M | -4.13M | -6.55M | -5.65M |
| Net Income to Common | -2.48M | -2.68M | -3.96M | -4.13M | -6.55M | -5.65M |
| Shares Outstanding (Basic) | 2.08M | 1.70M | 1.54M | 1.53M | 1.42M | 1.03M |
| Shares Outstanding (Diluted) | 2.08M | 1.70M | 1.54M | 1.53M | 1.42M | 1.03M |
| EPS (Basic) | -1.19 | -1.58 | -2.57 | -2.71 | -4.61 | -5.49 |
| EPS (Diluted) | -1.19 | -1.58 | -2.57 | -2.71 | -4.61 | -5.49 |
| Free Cash Flow | -2.31M | -2.29M | -2.82M | -4.11M | -4.65M | -4.74M |
| Free Cash Flow Per Share | -1.11 | -1.34 | -1.83 | -2.69 | -3.27 | -4.61 |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Margin | -81.01% | -95.23% | -168.16% | -177.78% | -393.57% | -495.12% |
| Profit Margin | -75.91% | -90.07% | -158.39% | -162.78% | -383.87% | -486.36% |
| Free Cash Flow Margin | -70.93% | -76.83% | -112.69% | -161.98% | -272.23% | -408.21% |
| EBITDA | -5.75M | |||||
| D&A For EBITDA | 757.00 | |||||
| EBIT | -2.64M | -2.83M | -4.20M | -4.52M | -6.72M | -5.75M |
| EBIT Margin | -81.01% | -95.23% | -168.16% | -177.78% | ||
| Revenue as Reported | 3.26M | 2.98M | 2.50M | 2.54M | 1.71M | 1.16M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 6.47M | 7.88M | 6.17M | 8.98M | 13.10M | 18.24M |
| Cash & Short-Term Investments | 6.47M | 7.88M | 6.17M | 8.98M | 13.10M | 18.24M |
| Prepaid Expenses | 154.31K | 113.29K | 393.95K | 103.83K | 556.09K | 252.36K |
| Other Current Assets | 28.00K | 53.00K | 28.00K | 500.00K | 227.04K | |
| Total Current Assets | 6.65M | 8.05M | 6.59M | 9.59M | 13.65M | 18.72M |
| Other Long-Term Assets | 313.92K | 313.92K | 313.92K | 1.02M | 666.93K | 691.93K |
| Total Assets | 6.97M | 8.36M | 6.90M | 10.61M | 14.72M | 19.82M |
| Accounts Payable | 322.54K | 258.11K | 283.62K | 240.83K | 287.36K | 362.47K |
| Accrued Expenses | 441.44K | 703.26K | 610.65K | 568.75K | 785.80K | 1.03M |
| Current Portion of Leases | 6.66K | 27.04K | ||||
| Other Current Liabilities | 131.00K | |||||
| Total Current Liabilities | 894.98K | 968.02K | 894.26K | 809.59K | 1.07M | 1.42M |
| Total Liabilities | 894.98K | 968.02K | 894.26K | 809.59K | 1.07M | 1.42M |
| Common Stock | 2.35K | 2.29K | 1.54K | 1.54K | 1.52K | 13.46K |
| Additional Paid-In Capital | 212.36M | 212.29M | 208.23M | 208.05M | 207.77M | 205.95M |
| Retained Earnings | -201.26M | -199.88M | -197.19M | -193.23M | -189.10M | -182.55M |
| Treasury Stock | -5.28M | -5.28M | -5.28M | -5.28M | -5.28M | -5.28M |
| Comprehensive Income & Other | 253.73K | 253.73K | 253.73K | 253.73K | 253.73K | 253.73K |
| Total Common Equity | 6.07M | 7.39M | 6.01M | 9.79M | 13.64M | 18.39M |
| Shareholders' Equity | 6.07M | 7.40M | 6.01M | 9.80M | 13.65M | 18.39M |
| Total Liabilities & Equity | 6.97M | 8.36M | 6.90M | 10.61M | 14.72M | 19.82M |
| Total Debt | 6.66K | 27.04K | ||||
| Net Cash (Debt) | 6.47M | 7.88M | 6.17M | 8.98M | 13.10M | 18.22M |
| Net Cash Per Share | 3.12 | 4.63 | 4.00 | 5.88 | 9.21 | 17.72 |
| Filing Date Shares Outstanding | 2.34M | 2.29M | 1.54M | 1.54M | 1.52M | 1.34M |
| Total Common Shares Outstanding | 2.34M | 2.29M | 1.54M | 1.54M | 1.52M | 1.34M |
| Working Capital | 5.76M | 7.08M | 5.69M | 8.78M | 12.58M | 17.30M |
| Book Value Per Share | 2.59 | 3.23 | 3.89 | 6.36 | 9.00 | 13.68 |
| Tangible Book Value | 6.07M | 7.39M | 6.01M | 9.79M | 13.64M | 18.39M |
| Tangible Book Value Per Share | 2.59 | 3.23 | 3.89 | 6.36 | 9.00 | 13.68 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -2.48M | -2.68M | -3.96M | -4.13M | -6.55M | -5.65M |
| Depreciation & Amortization | 27.04K | 35.48K | ||||
| Asset Writedown & Restructuring Costs | 1.79M | |||||
| Stock-Based Compensation | 93.13K | 64.79K | 171.81K | 283.08K | 511.48K | 410.44K |
| Change in Accounts Payable | -8.45K | 73.76K | 84.68K | -263.57K | -347.95K | 457.13K |
| Change in Other Net Operating Assets | 77.62K | 255.66K | 886.30K | 845.00 | -78.74K | 4.06K |
| Operating Cash Flow | -2.31M | -2.29M | -2.82M | -4.11M | -4.65M | -4.74M |
| Sale (Purchase) of Intangibles | -500.00K | |||||
| Investing Cash Flow | -500.00K | |||||
| Issuance of Common Stock | 4.00M | 4.00M | 11.45M | |||
| Financing Cash Flow | 4.00M | 4.00M | 11.45M | |||
| Net Cash Flow | 1.69M | 1.72M | -2.82M | -4.11M | -5.15M | 6.72M |
| Free Cash Flow | -2.31M | -2.29M | -2.82M | -4.11M | -4.65M | -4.74M |
| Free Cash Flow Margin | -70.93% | -76.83% | -112.69% | -161.98% | -272.23% | -408.21% |
| Free Cash Flow Per Share | -1.11 | -1.34 | -1.83 | -2.69 | -3.27 | -4.61 |
| Levered Free Cash Flow | -1.17M | -1.38M | -2.19M | -2.85M | -4.56M | -2.29M |
| Unlevered Free Cash Flow | -1.17M | -1.38M | -2.19M | -2.85M | -4.56M | -2.29M |
| Change in Working Capital | 69.17K | 329.42K | 970.98K | -262.73K | -426.69K | 461.19K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 4.80M | 4.97M | 6.15M | 5.32M | 4.32M | 17.27M |
| Enterprise Value | -1.67M | 851.79K | -684.63K | -4.46M | -9.52M | -2.39M |
| Last Close Price | 2.05 | 2.17 | 3.99 | 3.45 | 2.85 | 12.90 |
| PS Ratio | 1.47 | 1.67 | 2.46 | 2.09 | 2.53 | 14.88 |
| PB Ratio | 0.79 | 0.67 | 1.02 | 0.54 | 0.32 | 0.94 |
| P/TBV Ratio | 0.79 | 0.67 | 1.02 | 0.54 | 0.32 | 0.94 |
| EV/Sales Ratio | 0.29 | |||||
| Debt / Equity Ratio | 0.00 | 0.00 | ||||
| Net Debt / Equity Ratio | -1.07 | -1.06 | -1.03 | -0.92 | -0.96 | -0.99 |
| Net Debt / EBITDA Ratio | 3.17 | |||||
| Net Debt / FCF Ratio | 2.80 | 3.44 | 2.19 | 2.18 | 2.82 | 3.85 |
| Asset Turnover | 0.53 | 0.39 | 0.29 | 0.20 | 0.10 | 0.07 |
| Quick Ratio | 7.23 | 8.14 | 6.89 | 11.10 | 12.20 | 12.84 |
| Current Ratio | 7.43 | 8.32 | 7.37 | 11.84 | 12.72 | 13.18 |
| Return on Equity (ROE) | -47.04% | -40.00% | -50.12% | -35.27% | -40.90% | -36.88% |
| Return on Assets (ROA) | -26.80% | -23.21% | -30.02% | -22.29% | -24.32% | -21.77% |
| Return on Capital Employed (ROCE) | -43.50% | -38.30% | -70.00% | -46.10% | -49.20% | -31.20% |
| Earnings Yield | -58.13% | -53.92% | -64.36% | -77.78% | -151.53% | -32.69% |
| FCF Yield | -48.15% | -45.99% | -45.79% | -77.40% | -107.47% | -27.43% |
| Buyback Yield / Dilution | -34.68% | -10.40% | -0.86% | -7.44% | -38.38% | -60.81% |